Posdinemab

N/A

Report date: 2026/04/04 20:00:24

Base Information

Drug NamePosdinemab
Drug Alias NameJNJ-3657JNJ-63733657
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionMicrotubule-associated protein tau inhibitors
TargetsMicrotubule-associated protein tau
Therapy Area/IndicationsCognitive DysfunctionAlzheimer DiseaseDementia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[12] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJohnson & Johnson Innovative Medicine
China Registration ClassN/A

Develop Information

Active CompaniesFisher BioservicesJohnson & Johnson (China) Investment LtdCatalent Germany Schorndorf Gmbh +[4] 
Inactive CompaniesJanssen Pharmaceutical Kk
Active IndicationsCognitive DysfunctionAlzheimer Disease
Inactive IndicationsDementia

Other Information

ATC CodeN/A
Related LinksN/A